Congress Adopts New User Fee Program

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-07-02-2002, Volume 26, Issue 7

To fund expanded FDA operations designed to streamline drug development and approval, FDA and industry representatives have negotiated the Prescription Drug User Fee Act III.

Related Content:

Quality SystemsRegulatory WatchPharmaceutical Technology-07-02-2002
Novartis’ Radioligand Therapy Gains FDA Nod for Pediatric Patients
Navigating an Uncertain Regulatory Environment for mRNA-based Products
INTERPHEX 2024: Implementing Contamination Control Strategies in Cell and Gene Therapy Facilities